For holders of Evolution Petroleum's (NYSEMKT: EPM ) �perpetual non-convertible 8.5% Series A cumulative preferred stock, investors will receive�1/12th�of the 8.5% annualized amount, or approximately�$0.177083�per share, based on the�$25.00�per share liquidation preference.
Evolution's Series A preferred stock trades on the NYSE MKT (previously known as the Amex, or American Stock Exchange) under the symbol EPM.PR.A. However, since the securities have no stated maturity date, investors seeking liquidity will be limited to selling their shares in the secondary market and an active trading market for the shares may not develop for them.
Evolution is primarily engaged in the�acquisition, exploitation, and development of onshore properties for the production of crude oil and natural gas in the U.S.
Top Forestry Companies To Buy Right Now: Energen Corporation (EGN)
Energen Corporation, an energy holding company, engages in the development, acquisition, exploration, and production of oil, natural gas, and natural gas liquids in the continental United States. The company is also involved in the purchase, distribution, and sale of natural gas to residential, commercial, and industrial customers, as well as to other end-users of natural gas in central and north Alabama. In addition, it provides gas transportation services to industrial and commercial customers located on its distribution system. As of December 31, 2012, the company had approximately 750 million barrels of oil-equivalent proved, probable, and possible reserves. Energen Corporation was founded in 1929 and is headquartered in Birmingham, Alabama.
Advisors' Opinion:- [By Marc Bastow]
Oil and gas energy holding company Energen (EGN) raised its quarterly dividend 3.4% to 15 cents per share, payable on Mar. 3 to shareholder of record as of Feb. 14.
EGN Dividend Yield: 0.86%
Top 5 Prefered Stocks To Watch Right Now: QEP Midstream Partners LP (QEPM)
QEP Midstream Partners, LP (QEP), incorporated on April 19, 2013, is a limited partnership formed by QEP Resources, Inc. to owns, operates, acquires and develops midstream energy assets. The Company�� primary assets consist of ownership interests in four gathering systems and two Federal Energy Regulatory Commission (FERC)-regulated pipelines, through which it provides natural gas and crude oil gathering and transportation services. The Company�� assets are located in, or are within close proximity to, the Green River Basin located in Wyoming and Colorado, the Uinta Basin located in eastern Utah, and the portion of the Williston Basin located in North Dakota. As of December 31, 2012, the Company�� gathering systems had 1,475 miles of pipeline and an average gross throughput of 1.8 million british thermal units per hour of natural gas and 18,224 barrels of crude oil.
Green River System
The Company�� Green River System, located in western Wyoming, consists of three complimentary systems owned by Green River Gathering, Rendezvous Gas and Rendezvous Pipeline and gathers natural gas production from the Pinedale, Jonah and Moxa Arch fields. In addition to gathering natural gas, the system also gathers and stabilizes crude oil production from the Pinedale Field, transports the stabilized crude oil to an interstate pipeline interconnect, and gathers and handles produced and flowback water associated with well completion activities in the Pinedale Field. The Green River Gathering assets are comprised of 405 miles of natural gas gathering pipelines, 61 miles of crude oil gathering pipelines, 81 miles of water gathering pipelines and a 60-mile, FERC-regulated crude oil pipeline located in the Green River Basin. The Rendezvous Gas assets consist of three parallel, 103-mile high-pressure natural gas pipelines, with 1,032 million cubic feet per day of throughput capacity and 7,800 basic hydrogen peroxide of gas compression. Rendezvous Pipeline�� sole asset is a 21-mile, FERC-regu! lated natural gas transmission pipeline that provides gas transportation services from QEP�� Blacks Fork processing complex in southwest Wyoming to an interconnect with the Kern River Pipeline.
Vermillion Gathering System
The Vermillion Gathering System consists of gas gathering and compression assets located in southern Wyoming, northwest Colorado and northeast Utah, which, when combined, include 454 miles of low-pressure, gas gathering pipelines and 23,197 basic hydrogen peroxide of gas compression. The Vermillion Gathering System is primarily supported by life-of-reserves and long-term, fee-based gas gathering agreements with minimum volume commitments, which are designed to ensure that it will generate a certain amount of revenue over the life of the gathering agreement by collecting either gathering fees for actual throughput or payments to cover any shortfall. The primary customers on our Vermillion Gathering System include Questar, Samson Resources Corporation (Samson Resources), QEP and Chevron USA, Inc. (Chevron).
Three Rivers Gathering System
Three Rivers Gathering is a joint venture between QEP and Ute Energy Midstream Holdings, LLC (Ute Energy) that was formed to transport natural gas gathered by Uintah Basin Field Services, L.L.C., an indirectly owned subsidiary of QEP (Uintah Basin Field Services), and other third-party volumes to gas processing facilities owned by QEP and third parties. The Three Rivers Gathering System consists of gas gathering assets located in the Uinta Basin in northeast Utah, including approximately 50 miles of gathering pipeline and 4,735 basic hydrogen peroxide of gas compression.
Williston Gathering System
The Williston Gathering System is a crude oil and natural gas gathering system located in the Williston Basin in McLean County, North Dakota. The Williston Gathering System includes 17 miles of gas gathering pipelines, 17 miles of oil gathering pipelines 239 basic hydrogen peroxide o! f gas com! pression, and a crude oil and natural gas handling facility, located primarily on the Fort Berthold Indian Reservation.
The Company competes with Enterprise Products Partners, L.P., Western Gas and The Williams Companies, Inc.
Advisors' Opinion:- [By Jon C. Ogg]
QEP Midstream Partners L.P. (NYSE: QEPM) was started as Buy at Janney Capital, and note that four other firms started coverage earlier this week.
ServiceNow Inc. (NYSE: NOW) was started as Buy with a $55 price target at Canaccord Genuity.
- [By Dimitra DeFotis]
But things aren’t all bad. A spate of initial public offerings traded at nice prices Friday. Among them was QEP Midstream Partners (QEPM), an energy master limited partnership. (Press release here). More on IPOs from Bloomberg here.
- [By Lauren Pollock]
QEP Resources Inc.(QEP) plans to separate its midstream business, QEP Field Services Co., into a separate entity, including its interest in QEP Midstream Partners LP(QEPM).
Top 5 Prefered Stocks To Watch Right Now: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Lisa Levin]
Santarus (NASDAQ: SNTS) shares surged 37.64% to touch a new 52-week high of $31.96 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.
- [By David Williamson]
In this segment, health-care analyst David Williamson takes a look at the upcoming acquisition by Salix Pharmaceuticals (NASDAQ: SLXP ) of Santarus (NASDAQ: SNTS ) for about $2.6 billion. Salix is currently a maker of drugs for gastrointestinal diseases, and the immediately accretive deal will give Salix access to treatments for both diabetes and heartburn. Shares of both companies were up significantly on the news. David tells investors why shareholders should be pleased with this deal on both ends and what he thinks of the stock going forward.
Top 5 Prefered Stocks To Watch Right Now: Digital River Inc.(DRIV)
Digital River, Inc. provides end-to-end global cloud-commerce and marketing solutions. The company offers a range of services that enables its customers to establish an online sales channel. Its services include design, development, and hosting of online stores and shopping carts; store merchandising and optimization; order management; denied parties screening; export controls and management; tax compliance and management; fraud management; digital product delivery via download; physical product fulfillment; subscription management; online marketing, including email marketing; management of affiliate programs; paid search programs; payment processing services; Web site optimization, Web analytics, and reporting; and CD production and delivery services. The company also provides paid search advertising, search engine optimization, affiliate marketing, store optimization, multi-variant testing, and Web analytic and e-mail optimization services. In addition, it offers a range of payment processing services, such as multiple payment methods, fraud management, tax management, cloud-based billing, and other payment optimization services. The company sells its products and services through Internet and direct sales force. It serves software, consumer electronics, and computer and video game product manufacturers, as well as online channel partners, including retailers and affiliates in the United States, Austria, Brazil, China, Germany, Korea, Ireland, Japan, Luxembourg, Mexico, Singapore, Sweden, Taiwan, and the United Kingdom. Digital River, Inc. was founded in 1994 and is headquartered in Minnetonka, Minnesota.
Advisors' Opinion:- [By Alex Planes]
What: Shares of Digital River� (NASDAQ: DRIV ) are trading 8% higher in the afternoon after rocketing to an opening-bell gain of over 11% on Wednesday morning. Investors have cheered Digital River's strong first-quarter earnings and are reacting favorably to respectable (though not strong) guidance issued for the remainder of the fiscal year.
- [By Seth Jayson]
Digital River (Nasdaq: DRIV ) is expected to report Q2 earnings on July 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Digital River's revenues will expand 0.4% and EPS will wane -85.0%.